[
  {
    "objectID": "posts/meta-analysis-explained/index.html",
    "href": "posts/meta-analysis-explained/index.html",
    "title": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment",
    "section": "",
    "text": "Imagine that you are experiencing hair loss and you want to do something about it. You go online and find three main options for treatment. Minoxidil (commonly known as Rogaine), finasteride and dutasteride. Each one has studies showing it beats a placebo. Great. But which one actually works best?\nThe frustrating part for the consumer is that most clinical trials only test one treatment against a placebo. Sometimes they‚Äôll compare two treatments directly. But running trials that compare every possible pair? That‚Äôs expensive, takes time and as more treatments hit the market, it becomes basically impossible.\nSo how do researchers figure out which treatment ranks first when they‚Äôve never been directly compared?\nThat‚Äôs where network meta-analysis (NMA) comes in."
  },
  {
    "objectID": "posts/meta-analysis-explained/index.html#the-problem-too-many-treatments-not-enough-comparisons",
    "href": "posts/meta-analysis-explained/index.html#the-problem-too-many-treatments-not-enough-comparisons",
    "title": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment",
    "section": "",
    "text": "Imagine that you are experiencing hair loss and you want to do something about it. You go online and find three main options for treatment. Minoxidil (commonly known as Rogaine), finasteride and dutasteride. Each one has studies showing it beats a placebo. Great. But which one actually works best?\nThe frustrating part for the consumer is that most clinical trials only test one treatment against a placebo. Sometimes they‚Äôll compare two treatments directly. But running trials that compare every possible pair? That‚Äôs expensive, takes time and as more treatments hit the market, it becomes basically impossible.\nSo how do researchers figure out which treatment ranks first when they‚Äôve never been directly compared?\nThat‚Äôs where network meta-analysis (NMA) comes in."
  },
  {
    "objectID": "posts/meta-analysis-explained/index.html#indirect-comparisons-through-a-common-reference",
    "href": "posts/meta-analysis-explained/index.html#indirect-comparisons-through-a-common-reference",
    "title": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment",
    "section": "Indirect Comparisons Through a Common Reference",
    "text": "Indirect Comparisons Through a Common Reference\nNetwork meta-analysis is built on a simple idea. If we know how Treatment A compares to a placebo, and how Treatment B compares to that same placebo, we can estimate how A and B compare to each other.\nLet‚Äôs make this concrete with numbers.\nSuppose Study 1 finds that finasteride increases hair count by 15 hairs/cm¬≤ compared to placebo and Study 2 finds that minoxidil increases hair count by 12 hairs/cm¬≤ compared to placebo.\nIn this case, finasteride and minoxidil were never tested head-to-head. However, we can still infer that finasteride is roughly 3 hairs/cm¬≤ more effective (15 - 12 = 3).\nThis is called an indirect comparison. The placebo serves as the common comparator which acts as the bridge connecting the two treatments."
  },
  {
    "objectID": "posts/meta-analysis-explained/index.html#building-out-the-network",
    "href": "posts/meta-analysis-explained/index.html#building-out-the-network",
    "title": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment",
    "section": "Building Out the Network",
    "text": "Building Out the Network\nThe real power of NMA comes when we have many treatments and many studies. You can picture all the evidence as a network. Each treatment is a node, including placebo. Each line (edge) between nodes represents studies that directly compared those two treatments (direct comparison).\nThe magic of NMA is that it synthesizes all available evidence into a coherent framework. Even if Treatment X and Treatment Y were never tested against each other, we can estimate their relative effectiveness through their shared connections to other treatments in the network.\n\n\nCode\nimport networkx as nx\nimport matplotlib.pyplot as plt\n\nG = nx.Graph()\n\n# Nodes\ntreatments = [\n    \"Placebo\",\n    \"Minoxidil 2%\\n(topical)\",\n    \"Minoxidil 5%\\n(topical)\",\n    \"Minoxidil 0.25mg\\n(oral)\",\n    \"Minoxidil 5mg\\n(oral)\",\n    \"Finasteride 1mg\\n(oral)\",\n    \"Finasteride 5mg\\n(oral)\",\n    \"Dutasteride 0.5mg\\n(oral)\"\n]\n\nG.add_nodes_from(treatments)\n\n# Edges\nedges = [\n    (\"Placebo\", \"Minoxidil 2%\\n(topical)\", 6),\n    (\"Placebo\", \"Minoxidil 5%\\n(topical)\", 2),\n    (\"Placebo\", \"Finasteride 1mg\\n(oral)\", 4),\n    (\"Placebo\", \"Finasteride 5mg\\n(oral)\", 1),\n    (\"Placebo\", \"Dutasteride 0.5mg\\n(oral)\", 2),\n    (\"Minoxidil 2%\\n(topical)\", \"Minoxidil 5%\\n(topical)\", 2),\n    (\"Minoxidil 2%\\n(topical)\", \"Finasteride 1mg\\n(oral)\", 1),\n    (\"Finasteride 1mg\\n(oral)\", \"Finasteride 5mg\\n(oral)\", 1),\n    (\"Finasteride 1mg\\n(oral)\", \"Dutasteride 0.5mg\\n(oral)\", 2),\n    (\"Minoxidil 0.25mg\\n(oral)\", \"Placebo\", 1),\n    (\"Minoxidil 5mg\\n(oral)\", \"Placebo\", 1),\n]\n\nG.add_weighted_edges_from(edges)\n\nfig, ax = plt.subplots(figsize=(8, 6))\n\npos = nx.spring_layout(G, k=2, iterations=50, seed=42)\n\nnode_sizes = [800 + 400 * G.degree(node) for node in G.nodes()]\n\ncolor_map = []\nfor node in G.nodes():\n    if \"Placebo\" in node:\n        color_map.append(\"#95a5a6\")  # Gray for placebo\n    elif \"Dutasteride\" in node:\n        color_map.append(\"#e74c3c\")  # Red for dutasteride\n    elif \"Finasteride\" in node:\n        color_map.append(\"#3498db\")  # Blue for finasteride\n    else:\n        color_map.append(\"#2ecc71\")  # Green for minoxidil\n\nedge_weights = [G[u][v]['weight'] * 1.5 for u, v in G.edges()]\n\nnx.draw_networkx_edges(G, pos, width=edge_weights, alpha=0.6, edge_color=\"#7f8c8d\")\nnx.draw_networkx_nodes(G, pos, node_color=color_map, node_size=node_sizes, alpha=0.9)\nnx.draw_networkx_labels(G, pos, font_size=8, font_weight=\"bold\")\n\nlegend_elements = [\n    plt.scatter([], [], c=\"#95a5a6\", s=150, label=\"Placebo\"),\n    plt.scatter([], [], c=\"#e74c3c\", s=150, label=\"Dutasteride\"),\n    plt.scatter([], [], c=\"#3498db\", s=150, label=\"Finasteride\"),\n    plt.scatter([], [], c=\"#2ecc71\", s=150, label=\"Minoxidil\")\n]\nax.legend(handles=legend_elements, loc=\"upper left\", title=\"Treatment Type\")\n\nax.set_title(\"Network of Hair Loss Treatment Comparisons\\n(Gupta et al. 2022)\",\n             fontsize=14, fontweight=\"bold\")\nax.axis(\"off\")\nplt.tight_layout()\nplt.show()\n\n\n\n\n\n\n\n\nFigure¬†1: Network of treatment comparisons from the Gupta et al.¬†2022 study. Each node represents a treatment, and edges connect treatments that were directly compared in clinical trials. Node size reflects the number of studies involving that treatment, and edge thickness represents the number of direct comparisons.\n\n\n\n\n\nThe figure above shows the network from the Gupta study. Notice how placebo sits at the center, connecting to most treatments. This is typical since many trials compare a new treatment against placebo. The lines between treatments represent direct head-to-head comparisons from clinical trials.\nSometimes researchers have both direct evidence and indirect evidence for the same comparison. NMA combines them mathematically to get the most precise estimate possible. This combination of direct and indirect evidence is called mixed treatment comparison.\nMixed treatment comparison uses weighted averages. Larger sampled studies with less variability contribute more to the final estmation. Most modern NMA uses Bayesian statistics to quantify uncertainty and provide an estimation. This allows researchers to say things like ‚Äúthere‚Äôs a 96% chance Treatment A is the most effective.‚Äù."
  },
  {
    "objectID": "posts/meta-analysis-explained/index.html#case-study-ranking-hair-loss-treatments",
    "href": "posts/meta-analysis-explained/index.html#case-study-ranking-hair-loss-treatments",
    "title": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment",
    "section": "Case Study: Ranking Hair Loss Treatments",
    "text": "Case Study: Ranking Hair Loss Treatments\nIn 2022, Gupta and colleagues published a NMA in JAMA Dermatology (Gupta et al. 2022). They wanted to answer exactly this question, ‚ÄúAmong minoxidil, finasteride, and dutasteride, which works best for male pattern hair loss?‚Äù.\nThey took data from 23 clinical trials spanning several decades. The studies looked at different doses and formulations of the following treatments:\n\nOral dutasteride at 0.5 mg/day\nOral finasteride at 1 mg/day and 5 mg/day\nTopical minoxidil in 2% and 5% solutions\nOral minoxidil at 0.25 mg/day and 5 mg/day\nPlacebo\n\nMost studies compared a single treatment to placebo and only a few went head-to-head. By connecting all the studies through the network, the researchers could rank all treatments at once.\nThe results were clear. At 24 weeks, oral dutasteride (0.5 mg/day) came out on top. It had a SUCRA score of 96%. Then oral finasteride 5 mg at 88%. Topical minoxidil 5% at 80%. Oral finasteride 1 mg at 65%.\n\n\nCode\nimport altair as alt\nimport pandas as pd\n\n# SUCRA values from Gupta et al. 2022, Figure 3 (Column A: Total hair count at 24 weeks)\ndata = pd.DataFrame({\n    'Treatment': [\n        'Dutasteride 0.5mg (oral)',\n        'Finasteride 5mg (oral)',\n        'Minoxidil 5% (topical)',\n        'Finasteride 1mg (oral)',\n        'Minoxidil 2% (topical)',\n        'Minoxidil 5mg (oral)',\n        'Placebo',\n        'Minoxidil 0.25mg (oral)'\n    ],\n    'SUCRA': [95.7, 87.8, 80.4, 65.2, 55.3, 29.6, 13.5, 8.4]\n})\n\nchart = alt.Chart(data).mark_bar().encode(\n    x=alt.X('SUCRA:Q', title='SUCRA Value (%)', scale=alt.Scale(domain=[0, 100])),\n    y=alt.Y('Treatment:N', sort='-x', title=None),\n    color=alt.Color('SUCRA:Q', scale=alt.Scale(scheme='viridis'), legend=None)\n).properties(\n    title='Efficacy Ranking of Hair Loss Treatments (Gupta et al. 2022)',\n    width='container',\n    height=280\n)\n\nchart\n\n\n\n\n\n\n\n\n\n\nFigure¬†2: SUCRA rankings for hair loss treatments at 24 weeks (total hair count). Higher values indicate greater probability of being the most effective treatment. Data from Gupta et al.¬†2022."
  },
  {
    "objectID": "posts/meta-analysis-explained/index.html#under-the-hood",
    "href": "posts/meta-analysis-explained/index.html#under-the-hood",
    "title": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment",
    "section": "Under the Hood",
    "text": "Under the Hood\nAt its core, NMA relies on the consistency assumption which states that the indirect estimate should match up with the direct estimate when you have both available.\nSuppose, Study 1 shows A beats placebo by 10 units. Study 2 shows B beats placebo by 6 units. The indirect math says A beats B by 4 units. If a third study directly compares A and B and finds A wins by 4 units, we‚Äôve got consistency.\nHere‚Äôs roughly how the statistical model works.\nFirst, you define treatment effects. Each treatment gets an effect estimate relative to a common reference, usually placebo.\nThen, you combine direct and indirect evidence. When both exist for a comparison, they get combined using inverse-variance weighting. More precise estimates from larger studies carry more weight.\nNext, you estimate uncertainty. Bayesian methods give you not just point estimates but full probability distributions. So you know how confident to be in each ranking.\nFinally, you rank the treatments. There‚Äôs a metric called SUCRA, Surface Under the Cumulative Ranking Curve. It summarizes the probability that each treatment is best, second-best, third-best, and so on. A SUCRA of 100% means the treatment is definitely best and 0% means it‚Äôs definitely worst.\nThe Gupta study ran 200,000 iterations of Markov Chain Monte Carlo sampling. That‚Äôs a lot of computation to make sure the results were stable."
  },
  {
    "objectID": "posts/meta-analysis-explained/index.html#why-this-matters",
    "href": "posts/meta-analysis-explained/index.html#why-this-matters",
    "title": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment",
    "section": "Why This Matters",
    "text": "Why This Matters\nThink about someone standing in a pharmacy. They‚Äôre staring at the hair loss products. They want to know which one to buy.\nNetwork meta-analysis gives them something real. A ranking based on all available evidence. Not marketing. Not one cherry-picked study.\nBefore this analysis, you might read one study showing finasteride works. Another showing minoxidil works. And you‚Äôd have no way to compare them. The NMA pulls together decades of clinical research into a clear order.\n\nDutasteride 0.5 mg/day (most effective)\nFinasteride 5 mg/day\nOral minoxidil 5 mg/day\nFinasteride 1 mg/day (the FDA-approved dose)\nTopical minoxidil 5%\nTopical minoxidil 2%\nOral minoxidil 0.25 mg/day\n\nThis ranking is useful for patients and doctors to make informed decisions. It also shows gaps in the evidence, for example, dutasteride‚Äôs long-term efficacy at 48 weeks was not well-studied. This gives researchers a clear direction for future research."
  },
  {
    "objectID": "posts/meta-analysis-explained/index.html#the-limitations",
    "href": "posts/meta-analysis-explained/index.html#the-limitations",
    "title": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment",
    "section": "The Limitations",
    "text": "The Limitations\nNetwork meta-analysis isn‚Äôt magic. It depends on some key assumptions holding up.\nTransitivity: The studies being combined need to be similar enough that indirect comparisons make sense. If Study 1 enrolled young patients and Study 2 enrolled elderly patients, comparing their results through a common placebo might mislead you.\nConsistency: When you have both direct and indirect evidence, they should roughly agree. Big inconsistencies suggest problems with assumptions.\nPublication bias: If negative studies never get published, your network only includes treatments that looked like they worked. That can inflate the effectiveness estimates.\nThe Gupta study dealt with these issues. They assessed study quality using the Cochrane risk-of-bias tool. They evaluated network-wide evidence quality using the CINeMA framework. Gupta found that the evidence quality ranged from low to moderate for most comparisons. This is a common finding in NMA which reflects the imperfect nature of real-world clinical evidence."
  },
  {
    "objectID": "posts/meta-analysis-explained/index.html#conclusion",
    "href": "posts/meta-analysis-explained/index.html#conclusion",
    "title": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment",
    "section": "Conclusion",
    "text": "Conclusion\nNetwork meta-analysis takes scattered clinical evidence and turns it into something useful. Rankings you can actually act on.\nTreatments can be compared indirectly through common reference points. That lets us answer questions no single trial could handle such as, ‚ÄúWhich of these many treatments is actually best?‚Äù.\nFor hair loss, Gupta‚Äôs 2022 analysis gave a clear answer, oral dutasteride leads with higher-dose finasteride coming in next with topical minoxidil trailing behind. This NMA study is not the final word. New head-to-head trials will come along, the network will grow and estimates will become more precise.\nThe next time you are facing a decision with multiple options and conflicting evidence, look for a network meta-analysis. It might cut through the noise and show you what the data actually says."
  },
  {
    "objectID": "blog.html",
    "href": "blog.html",
    "title": "Blog",
    "section": "",
    "text": "What Your Pharmacy Shelves Won‚Äôt Tell You About Hair Loss Treatment\n\n\nA Data Science Approach to Comparing Treatments with Network Meta-Analysis\n\n\n\ndata science\n\nstatistics\n\nnetwork meta-analysis\n\nhealth\n\n\n\n\n\n\n\n\n\nJan 17, 2026\n\n\nJiro Amato\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "about.html#about-me",
    "href": "about.html#about-me",
    "title": "About",
    "section": "üë®‚Äçü¶± About Me",
    "text": "üë®‚Äçü¶± About Me\nI am an aspiring Data Scientist based in Vancouver currently enrolled in the Master of Data Science at the University of British Columbia. My journey towards this career shift began during my time as an Investment Analyst in Web3, where I discovered my passion for data as I honed my skills in data analytics and critical thinking to evaluate startups, make investment decisions, and assess market trends.\nDuring my role as an Investment Analyst, my interest in Machine Learning was also ignited through seeing many firms leverage ML models in research and in practice through Algorithmic Trading. Combined with a background in finance and tech sales, I believe I can bridge the gap between technical analysis and business insight.\nWhat excites me is the nascent landscape of Data Science which means that there is a lot to be done in terms of research and innovation in all domains. Let‚Äôs uncover the stories in your data and transform insights into impactful actions."
  },
  {
    "objectID": "about.html#projects",
    "href": "about.html#projects",
    "title": "About",
    "section": "üìë Projects",
    "text": "üìë Projects\n\nStock Trend Prediciton with NLP üìà\nJUL 2024 - Explored different Natural Language Processing techinques in order to process text data. - Conducted grid search to optimize for the best sentiment analysis model. - Conducted experiments on base time series models which include AR, MA, ARIMA, and SARIMAX models. - Ulitized Recurrent Neural Networks (RNNs) like LSTM in order combine sentiment data with stock price data."
  },
  {
    "objectID": "about.html#connect-with-me",
    "href": "about.html#connect-with-me",
    "title": "About",
    "section": "ü§ù Connect with Me",
    "text": "ü§ù Connect with Me\nFeel free to reach out to me on LinkedIn.\n\n\n\nImage3\n\n\n\n‚ÄúAlways be ready to adjust, recalibrate, and stay after it to become better, somehow.‚Äù - David Goggins"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Home",
    "section": "",
    "text": "Lots of exciting things to come but for now, please refer to the About me page üòä"
  }
]